51 studies found for:    MK-2206
Show Display Options
Rank Status Study
1 Unknown  Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC)
Condition: Non Small Cell Lung Cancer
Intervention: Drug: MK2206
2 Completed A Phase I Study of MK2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (2206-003 AM5)
Condition: Locally Advanced, Metastatic Solid Tumors
Interventions: Drug: MK-2206 combined with carboplatin + paclitaxel;   Drug: MK-2206 combined with docetaxel;   Drug: MK-2206 combined with erlotinib
3 Active, not recruiting MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer
Conditions: Estrogen Receptor Positive;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer
Interventions: Drug: Akt Inhibitor MK2206;   Drug: Anastrozole;   Drug: Fulvestrant;   Other: Laboratory Biomarker Analysis
4 Completed
Has Results
MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma
Condition: Colorectal Neoplasms
Intervention: Drug: MK-2206 + AZD6244
5 Withdrawn Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: MK-2206;   Drug: Exemestane;   Drug: Goserelin
6 Terminated
Has Results
Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer
Conditions: Colon Cancer;   Rectal Cancer
Intervention: Drug: MK-2206
7 Recruiting Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
Conditions: Pancreatic Adenocarcinoma;   Recurrent Pancreatic Carcinoma;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unresectable Pancreatic Cancer
Interventions: Drug: Akt Inhibitor MK2206;   Drug: Dinaciclib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
8 Terminated Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Positive;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer
Interventions: Drug: Akt Inhibitor MK2206;   Other: Laboratory Biomarker Analysis;   Drug: Lapatinib Ditosylate;   Other: Pharmacogenomic Study;   Other: Pharmacological Study
9 Completed A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer
Conditions: Ovarian Sarcoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Akt Inhibitor MK2206;   Other: Laboratory Biomarker Analysis
10 Completed Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)
Conditions: PANCREAS;   Neuroendocrine
Intervention: Drug: MK-2206
11 Active, not recruiting MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer
Conditions: Adult Solid Neoplasm;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer
Interventions: Drug: Akt Inhibitor MK2206;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Pharmacological Study
12 Completed Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: Akt inhibitor MK2206;   Drug: lapatinib ditosylate;   Other: pharmacological study;   Other: laboratory biomarker analysis
13 Active, not recruiting PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer
Condition: Endometrial Cancer
Intervention: Drug: MK-2206
14 Completed A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007)
Condition: Solid Tumors
Interventions: Drug: MK2206 every other day;   Drug: MK2206 once weekly
15 Completed Dose Escalation Study With MK2206 in Patients With Locally Advanced or Metastatic Solid Tumors (2206-002)
Conditions: Locally Advanced Tumors;   Metastatic Solid Tumors;   Cancer;   Neoplasms
Intervention: Drug: MK2206
16 Withdrawn MK-2206 for Recurrent Malignant Glioma
Condition: Malignant Glioma
Intervention: Drug: MK-2206
17 Withdrawn MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: MSK-2206;   Drug: Exemestane;   Drug: Goserelin
18 Recruiting Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
Conditions: Adult Solid Neoplasm;   Hormone-Resistant Prostate Cancer;   Recurrent Melanoma;   Recurrent Prostate Carcinoma;   Recurrent Renal Cell Carcinoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Skin Melanoma
Interventions: Drug: Akt Inhibitor MK2206;   Drug: Hydroxychloroquine;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
19 Recruiting Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Recurrent Breast Carcinoma;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Akt Inhibitor MK2206;   Drug: Anastrozole;   Drug: Goserelin Acetate;   Other: Laboratory Biomarker Analysis;   Procedure: Neoadjuvant Therapy;   Other: Pharmacological Study;   Procedure: Therapeutic Conventional Surgery
20 Active, not recruiting
Has Results
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
Conditions: Recurrent Oral Cavity Adenoid Cystic Carcinoma;   Recurrent Salivary Gland Carcinoma;   Salivary Gland Adenoid Cystic Carcinoma;   Stage IVA Major Salivary Gland Carcinoma;   Stage IVA Oral Cavity Adenoid Cystic Carcinoma;   Stage IVB Major Salivary Gland Carcinoma;   Stage IVB Oral Cavity Adenoid Cystic Carcinoma;   Stage IVC Major Salivary Gland Carcinoma;   Stage IVC Oral Cavity Adenoid Cystic Carcinoma
Interventions: Drug: Akt Inhibitor MK2206;   Other: Laboratory Biomarker Analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years